FDA Issues Complete Response Letter for neffy® (epinephrine
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under...
Source: globenewswire.com
📰 Human Use News
Page 46 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under allergen-induced allergic rhinitis conditions FDA...
United States Monique Allaire Richard Lowenthal Justin Chakma Laura Oneill Committee For Medicinal Products Human
Source: marketscreener.com
Why ARS Pharmaceuticals (SPRY) Shares Are Plunging Today - ARS Pharmaceuticals (NASDAQ:SPRY)
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for 
Pharma Neffy Committee For Medicinal Products Human European Medicines Agency Pharmaceuticals Inc Complete Response Letter Drug Application
Source: benzinga.com
FDA declines to approve nasal spray alternative to EpiPen
In a surprise to its makers, a nasal spray intended to be an alternative to the EpiPen was sent back by the FDA, the company announced.
United States Richard Lowenthal Pharmaceuticals On Asthma Network European Medicines Agency Advisory Committee
Source: ksby.com
FDA denies nasal spray alternative to EpiPen
In a surprise to its makers, a nasal spray intended to be an alternative to the EpiPen was sent back by the FDA, the company announced.
United States Richard Lowenthal Advisory Committee European Medicines Agency Committee For Medicinal Products Human Drug Administration
Source: kxxv.com
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000...
United States Menarini Industrie Farmaceutiche Riunite Elcin Barker Ergun Giuseppe Curigliano Menarini Group Stemline Therapeutics Inc
Source: prnewswire.com
WHO and the pandemic flu "conspiracies" – FULL report from the BMJ and The Bureau of Investigative Journalism 2010 – Engineering Evil
2010 report posted for filing Conflicts of Interest WHO and the pandemic flu "conspiracies" Deborah Cohen, features editor, BMJ, Philip Carter, journalist, The Bureau of Investigative Journalism, London dcohen@bmj.com Key scientists advising the World Health Organization on planning for an influenza pandemic had done paid work for pharmaceutical firms that stood to gain from the…
Source: engineeringevil.com
Guerbet: 2023 half-year results -September 20, 2023 at 11:46 am EDT
Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in...
Source: marketscreener.com
FDA declines to approve nasal spray alternative to EpiPen
In a surprise to its makers, a nasal spray intended to be an alternative to the EpiPen was sent back by the FDA, the company announced.
United States Richard Lowenthal Committee For Medicinal Products Human Allergy Drugs Advisory Committee Drug Administration Pharmaceuticals On
Source: wtkr.com
FDA declines to approve nasal spray alternative to EpiPen
In a surprise to its makers, a nasal spray intended to be an alternative to the EpiPen was sent back by the FDA, the company announced.
United States Richard Lowenthal European Medicines Agency Advisory Committee Asthma Network Drug Administration
Source: krtv.com